Edition:
India

Savara Inc (SVRA.OQ)

SVRA.OQ on NASDAQ Stock Exchange Global Select Market

12.69USD
1:30am IST
Change (% chg)

$0.37 (+3.00%)
Prev Close
$12.32
Open
$12.34
Day's High
$12.82
Day's Low
$12.28
Volume
49,325
Avg. Vol
84,979
52-wk High
$17.11
52-wk Low
$5.07

Latest Key Developments (Source: Significant Developments)

Savara Inc Files For Mixed Shelf Of Up To $250 Million
Saturday, 30 Jun 2018 

June 29 (Reuters) - Savara Inc ::SAVARA INC FILES FOR MIXED SHELF OF UP TO $250 MILLION – SEC FILING.  Full Article

Savara Inc - Development Award Raised to $6.7 Mln - Sec Filing
Thursday, 30 Nov 2017 

Nov 30 (Reuters) - Savara Inc ::SAVARA- ON NOV 28 ENTERED INTO AMENDMENT EFFECTIVE SEPT 30,TO RESEARCH PROGRAM AWARD LETTER AGREEMENT BETWEEN CO, CYSTIC FIBROSIS FOUNDATION THERAPEUTICS.SAVARA INC - UNDER AMENDMENT, AMOUNT OF DEVELOPMENT AWARD AVAILABLE TO SAVARA WAS INCREASED BY $5 MILLION TO AN AGGREGATE OF $6.7 MILLION - SEC FILING.  Full Article

Savara ‍Received $5 Mln Award For Development Of Aerovanc​
Wednesday, 29 Nov 2017 

Nov 29 (Reuters) - Savara Inc ::SAVARA INC - ‍RECEIVED $5 MILLION AWARD FROM CYSTIC FIBROSIS FOUNDATION THERAPEUTICS FOR DEVELOPMENT OF AEROVANC​.  Full Article

Savara posts Q3 loss per share $0.28
Thursday, 9 Nov 2017 

Nov 8 (Reuters) - Savara Inc :Savara reports third quarter 2017 financial results and provides business update.Q3 loss per share $0.28.Q3 earnings per share view $-0.58 -- Thomson Reuters I/B/E/S.Anticipating complete enrollment in molgradex phase 3 impala study in q1 2018​.Initiating phase 2A study of Molgradex for treatment of NTM in early 2018​.Expecting top-line results from aironite phase 2 indie study in h1 2018​.Research and development expenses were $5.0 million for three-months ended September 30, 2017, compared with $2.1 million for Q3 of 2016​.  Full Article

SAVARA ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK
Wednesday, 25 Oct 2017 

Oct 25 (Reuters) - Savara Inc ::SAVARA ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAVARA INC - ‍PRICES UNDERWRITTEN PUBLIC OFFERING OF 5.25 MILLION SHARES OF ITS COMMON STOCK AT A PRICE TO PUBLIC OF $7.85 PER SHARE​.  Full Article

Savara announces proposed public offering of common stock
Wednesday, 25 Oct 2017 

Oct 24 (Reuters) - Savara Inc :Savara announces proposed public offering of common stock.  Full Article

Savara reports completion of enrollment
Wednesday, 18 Oct 2017 

Oct 18 (Reuters) - Savara Inc ::Savara reports completion of enrollment in phase 2 clinical trial of aironite for the treatment of hfpef.Savara Inc - ‍expects that top-line results from indie-hfpef study will be available in first half of 2018​.  Full Article

Mast Therapeutics provides business update
Monday, 26 Sep 2016 

Mast Therapeutics Inc : Mast Therapeutics provides business update . Company has begun to wind down its vepoloxamer programs in sickle cell disease and heart failure . Company is planning to initiate a process to evaluate partnership opportunities for its assets . Co to make $10 million prepayment on debt facility triggered by recently announced results of phase 3 study of vepoloxamer in early Oct 2016 . Expects wind down activities will be completed in Q4 of 2016 .Company estimates that its operating expenses for 2017 will be in range of $9 to $10 million.  Full Article

Mast Therapeutics Q2 loss per share $0.05
Tuesday, 9 Aug 2016 

Mast Therapeutics Inc : Q2 loss per share $0.05 . Mast therapeutics reports second quarter 2016 financial results .Q2 earnings per share view $-0.06 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Savara Reports Q1 Loss Per Share $0.88

* SAVARA REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE